• RCTs in Economics

      May 26, 2011 at 8:00 pm
      Don Taylor

    Marc Bellemare with interesting thoughts on the positives and negatives of using RCTs in development economics. I am chewing on what these observations mean for U.S. health policy, and when the sentiment ‘we wish we could do a RCT but we can’t’ is true, and when it is not. Thoughts?

    Comments closed
     
      Health Policy

    • by Jess on May 26th, 2011 at 20:49

      Ethics is as import for RCTs in development economics as it is for RCTs in medicine. While medical researchers have not always lived up to their own standards in this area, the development profession (my own field) has a particularly poor track record in studying – and changing – the lives of poor people. While the ethics of conducting RCTs in development economics has received considerable attention, as far as I am aware there is no development economics equivalent to the Helsinki Declaration.

      To use Bellemare’s example, is it ethical to observe children’s school attendance and performance, but to not to provide deworming medication to the control group? Can equipose truly be assumed? In other words, would YOU rather your child was in the treatment group or the control group?

      [top]

      • by Don Taylor on May 26th, 2011 at 22:05

        @Jess
        Interesting point about different disciplines having different levels of ethics/conventions about conduct of research. Similarly, I think that RCTs in pharmaceuticals are ahead of the game on aggregating/reporting results.

        I think that in pharma research, most participants would rather be in treatment group as well, because it holds out hope for a ‘miracle cure’ but it does seem different if control is to observed something (truancy) that we are almost certain is bad.

        [top]

    • by Brad F on May 27th, 2011 at 05:56

      Don
      On the ethics of RCTs and pharma, things are changing. Are they (pharma), playing by the rules? You be the judge:

      http://www.vanityfair.com/politics/features/2011/01/deadly-medicine-201101

      Brad

      [top]

    • by Don Taylor on May 27th, 2011 at 09:23

      @Brad F
      Interesting article. This makes the point that just having a set of rules and procedures for reporting results doesn’t mean everything is as it should be. The pharma RCTs world is big and has many issues and many involved. Many of my questions go to issues of RCTs for other interventions, like palliative care. Or disease management. You could have the issue of internal validity straight (x causes y), but have no external validity (not replicable). I will try and sketch out some of these thoughts more clearly and post next week.

      [top]